K36 Therapeutics

Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics

Biotech & Life Sciences

Sector

Seed

Stage

Biotechnology

Model

01Company Overview

Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.

02Backed By1 investor

03Similar Companies

E

EpiTherapeutics

Biotech & Life Sciences

→

T

OP

CP

I

04Startup DNA

9

signals

Sectors
Business Model
Technology